Ching‐Ming Yeh

591 total citations
18 papers, 466 citations indexed

About

Ching‐Ming Yeh is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Ching‐Ming Yeh has authored 18 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Pharmacology. Recurrent topics in Ching‐Ming Yeh's work include Renin-Angiotensin System Studies (11 papers), Blood Pressure and Hypertension Studies (10 papers) and Hormonal Regulation and Hypertension (9 papers). Ching‐Ming Yeh is often cited by papers focused on Renin-Angiotensin System Studies (11 papers), Blood Pressure and Hypertension Studies (10 papers) and Hormonal Regulation and Hypertension (9 papers). Ching‐Ming Yeh collaborates with scholars based in United States, Switzerland and France. Ching‐Ming Yeh's co-authors include Sujata Vaidyanathan, H. A. Dieterich, Marie‐Noëlle Bizot, William P. Dole, Dan Howard, Mojdeh Maboudian, R. Camisasca, Charlie W. Zhao, Christine Reynolds and Romain Séchaud and has published in prestigious journals such as Clinical Pharmacokinetics, Journal of Hypertension and British Journal of Clinical Pharmacology.

In The Last Decade

Ching‐Ming Yeh

18 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ching‐Ming Yeh United States 13 271 224 59 55 45 18 466
B. H. Ch. Stricker Netherlands 10 194 0.7× 99 0.4× 25 0.4× 49 0.9× 81 1.8× 16 551
Marie‐Noëlle Bizot France 8 221 0.8× 217 1.0× 14 0.2× 73 1.3× 61 1.4× 8 420
Irl B. Hirsch United States 7 69 0.3× 746 3.3× 75 1.3× 33 0.6× 179 4.0× 14 919
Michael J. Knauer Canada 12 78 0.3× 56 0.3× 47 0.8× 191 3.5× 94 2.1× 25 603
P. J. Voogd Netherlands 8 324 1.2× 55 0.2× 25 0.4× 41 0.7× 26 0.6× 14 497
Angela Cheng-Lai United States 13 160 0.6× 69 0.3× 25 0.4× 25 0.5× 60 1.3× 32 398
Petr Kujal Czechia 15 253 0.9× 240 1.1× 25 0.4× 7 0.1× 58 1.3× 34 514
Jutta Miller United States 12 44 0.2× 58 0.3× 42 0.7× 36 0.7× 64 1.4× 20 483
Sung Eun Sim South Korea 6 133 0.5× 87 0.4× 26 0.4× 136 2.5× 68 1.5× 19 657
HIROSHI SEKINO Japan 9 222 0.8× 169 0.8× 15 0.3× 13 0.2× 162 3.6× 67 619

Countries citing papers authored by Ching‐Ming Yeh

Since Specialization
Citations

This map shows the geographic impact of Ching‐Ming Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching‐Ming Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching‐Ming Yeh more than expected).

Fields of papers citing papers by Ching‐Ming Yeh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching‐Ming Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching‐Ming Yeh. The network helps show where Ching‐Ming Yeh may publish in the future.

Co-authorship network of co-authors of Ching‐Ming Yeh

This figure shows the co-authorship network connecting the top 25 collaborators of Ching‐Ming Yeh. A scholar is included among the top collaborators of Ching‐Ming Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching‐Ming Yeh. Ching‐Ming Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Boschmann, Michael, Jürg Nussberger, Stefan Engeli, et al.. (2012). Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin–angiotensin system activity in obese hypertensive patients. Journal of Hypertension. 30(3). 561–566. 21 indexed citations
2.
Abdulla, Salim, Mbaraka Amuri, Abdunoor M. Kabanywanyi, et al.. (2010). Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malaria Journal. 9(1). 253–253. 21 indexed citations
3.
Jarugula, Venkateswar, Ching‐Ming Yeh, Dan Howard, et al.. (2010). Influence of Body Weight and Gender on the Pharmacokinetics, Pharmacodynamics, and Antihypertensive Efficacy of Aliskiren. The Journal of Clinical Pharmacology. 50(12). 1358–1366. 14 indexed citations
4.
Hu, Pei, Michael G. Bartlett, Ji Jiang, et al.. (2010). Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects. Clinical Drug Investigation. 30(4). 221–228. 3 indexed citations
5.
Sunkara, Gangadhar, et al.. (2010). Assessment of Ethnic Differences in the Pharmacokinetics and Pharmacodynamics of Valsartan. Journal of Bioequivalence & Bioavailability. 2(6). 9 indexed citations
6.
Ayalasomayajula, Surya, Ching‐Ming Yeh, Sujata Vaidyanathan, et al.. (2008). Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects. The Journal of Clinical Pharmacology. 48(7). 799–811. 14 indexed citations
7.
Vaidyanathan, Sujata, Michael G. Bartlett, H. A. Dieterich, et al.. (2008). Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended‐Release Isosorbide‐5‐Mononitrate in Healthy Subjects. Cardiovascular Therapeutics. 26(4). 238–246. 9 indexed citations
8.
Vaidyanathan, Sujata, Mojdeh Maboudian, Ching‐Ming Yeh, et al.. (2008). A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Current Medical Research and Opinion. 24(8). 2313–2326. 17 indexed citations
9.
Ayalasomayajula, Surya, Ching‐Ming Yeh, Marie‐Noëlle Bizot, et al.. (2008). A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Current Medical Research and Opinion. 24(3). 717–726. 21 indexed citations
10.
Boomsma, Frans, et al.. (2008). Measurement of bioactive renin concentration and renin activity in the presence of exogenous renin substrate: effect of the oral direct renin inhibitor aliskiren. Journal of the Renin-Angiotensin-Aldosterone System. 9(1_suppl). S12–S12. 1 indexed citations
11.
Vaidyanathan, Sujata, et al.. (2007). Pharmacokinetics, Safety, and Tolerability of the Oral Renin Inhibitor Aliskiren in Patients With Hepatic Impairment. The Journal of Clinical Pharmacology. 47(2). 192–200. 46 indexed citations
12.
Vaidyanathan, Sujata, Christine Reynolds, Ching‐Ming Yeh, et al.. (2007). Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects. The Journal of Clinical Pharmacology. 47(4). 453–460. 43 indexed citations
13.
Vaidyanathan, Sujata, et al.. (2006). Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. British Journal of Clinical Pharmacology. 62(6). 690–698. 58 indexed citations
14.
Zhao, Charlie W., Sujata Vaidyanathan, Ching‐Ming Yeh, Mojdeh Maboudian, & H. A. Dieterich. (2006). Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics. 45(11). 1125–1134. 57 indexed citations
15.
Kaplan, Bruce, Herwig‐Ulf Meier‐Kriesche, Romain Séchaud, et al.. (2005). Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co‐administered enteric‐coated mycophenolate sodium. Clinical Transplantation. 19(4). 551–558. 39 indexed citations
16.
Scott, Graham, et al.. (2004). Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects. The Journal of Clinical Pharmacology. 44(2). 193–199. 11 indexed citations
17.
Yeh, Ching‐Ming, et al.. (2002). Pharmacokinetics of Multiple Doses of Valsartan in Patients With Heart Failure. Journal of Cardiovascular Pharmacology. 40(5). 801–807. 26 indexed citations
18.
Smith, Malcolm C., Tianling Chen, Horst Schran, et al.. (2000). OctreoTher<sup>TM</sup>: Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy. Digestion. 62(Suppl. 1). 69–72. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. H. Ch. Stricker Breakdown of academic impact, for papers by Marie‐Noëlle Bizot Breakdown of academic impact, for papers by Irl B. Hirsch Breakdown of academic impact, for papers by Michael J. Knauer Breakdown of academic impact, for papers by P. J. Voogd Breakdown of academic impact, for papers by Angela Cheng-Lai Breakdown of academic impact, for papers by Petr Kujal Breakdown of academic impact, for papers by Jutta Miller Breakdown of academic impact, for papers by Sung Eun Sim Breakdown of academic impact, for papers by HIROSHI SEKINO
Rankless by CCL
2026